Biophan-die neue Microsoft?!
Seite 52 von 113 Neuester Beitrag: 26.07.23 00:01 | ||||
| Eröffnet am: | 15.05.04 09:58 | von: aida73 | Anzahl Beiträge: | 3.824 |
| Neuester Beitrag: | 26.07.23 00:01 | von: MrTrillion3 | Leser gesamt: | 388.781 |
| Forum: | Hot-Stocks | Leser heute: | 25 | |
| Bewertet mit: |  | |||
| Seite: < 1 | ... | 49 | 50 | 51 | | 53 | 54 | 55 | ... 113 > | ||||
" We have spent the past week in Germany, meeting with AMRIS and MRC, a subsidiary AMRIS is acquiring, which conducts consulting and testing, and with Michael Friebe, Ph.D., AMRIS founder and President, Andreas Melzer, M.D., AMRIS' Scientific Director and Chief Technology Officer, Gregor Schaefers, Managing Director of MRC, and with their customers and ours, planning the integration of Biophan-Europe. Things are going well and we will close the paperwork for the three company integration within the next few weeks. We extended the letter of understanding to allow us to comply with all related U.S. and German laws," stated Michael Weiner, CEO of Biophan and Michael Friebe, CEO of AMRIS, in a joint statement made in Castrop-Rauxel at the headquarters of AMRIS, which is being renamed Biophan-Europe.
" While in Germany we met with many customers and prospects of Biophan and AMRIS to explore integration issues, including meetings with Boston Scientific personnel to explore how AMRIS will assist Biophan in the support of Boston Scientific. Boston Scientific has a joint development agreement with Biophan across several Boston Scientific divisions, and also has an existing relationship with AMRIS and MRC," stated Michael Weiner.
AMRIS technologies and facilities allow for a significant expansion of Biophan's capabilities, including access to dozens of MRI devices and components through the AMRIS facilities and those of its affiliate, Tomovation, also headed by Dr. Friebe. Tomovation companies distribute, install, and refurbish MRI devices for all the major MRI companies, and this significantly expands the availability of devices for testing, including access to its unique animal testing facilities which can do MRI imaging of very large animals including horses, sheep and large farm swine. Under the terms of the expanding relationship, these facilities will also be made available to Biophan-Europe. Tomovation has ongoing working relationships with Siemens, Philips, and G.E.
" Successful development of MRI-safe and image-compatible medical devices requires extensive testing across a variety of MRI devices, with varying coil types, magnet sizes, and RF capabilities during both the early stage design phase and the later stage clinical trial phases. As the expansion of MRI-safe and image-compatible medical devices continues and expands, both Biophan and its customers, as well as companies pursuing development of their own MRI-safe and image-compatible devices, need access to equipment and expertise covering the full range of MRI devices installed in the field all around the world. AMRIS is quite unique in this regard, and significantly expands and complements the capabilities already provided by Biophan's relationships," Weiner explained.
Hier wird was ganz eigenartiges geplant!!!
Amris ist klar.Die haben auch noch Verbindungen zu Siemens usw.
Dazu kommt MRC http://www.mrcomp.com/4082.html Schaut euch hier mal die Produktpalette und die Führung der Firma an und stellt selber für euch fest,wohin Weiners Reise geht.
hui das Puzzel setzt sich zusammen.Wir sollten alle gespannt,mit was für einer News und Zusammenarbeit der Weiner seine Anleger überrascht
Eins dürfte jetzt auch nach der obrigen News klar sein.Der Bsx-Deal ist mehr als gewiß!!
leider waren die Schlußumsätze nicht unbedingt der Bringer aber Tageshoch!!!
Wir können auf morgen schon gespannnt sein und ich freue mich schon auf die richtige Meldung in kürze,wo der Big deal bekannt gegeben wird.Hierzu wird immer wieder BSX erwähnt und in der heutige News bereits ,in einem Absatz, 4x.
Biophan wird in einer der bekanntesten Buisness-Magazine der USA genannt und hervorgehoben.
Zitat:Im Artikel BusinessWeek wird Biophan als einer von sieben nanotechnologyspielern im healthcaresektor zusammen mit General Electric, Johnson u. Johnson, der NASA und anderen verzeichnet.
es wird ein gutes Biophan-Jahr
Biophan Noted in BusinessWeek Report on
Nanotechnology Science and Marketplace
Company Named Among Key Players in Healthcare Sector
ROCHESTER, N.Y.—February 11, 2005--Biophan Technologies, Inc. (OTCBB:BIPH), a developer of next-generation biomedical technology, has announced that the Company has been included in BusinessWeek magazine’s (February 14, 2005 issue, page 67) cover story about the latest innovations in nanotechnology, the multi-billion-dollar marketplaces nanoscience currently enable, and the potential for significant further growth.
The BusinessWeek cover story, entitled “The Business of Nanotech,” describes the progression of nanotechnology from the laboratories to a burgeoning marketplace involving key industries, including healthcare, automotive, energy, computers and semiconductors, advanced consumer materials, and many others.
In the BusinessWeek article, Biophan is listed as one of seven nanotechnology players in the healthcare sector along with General Electric, Johnson & Johnson, NASA, and others.
The article quotes nanotechnology market researchers who project the 2005 nanotechnology marketplace will reach an estimated $13 billion. By the end of the decade, however, the nanotechnology market will grow to an estimated $292 billion, according to the industry observers.
“The BusinessWeek article does an excellent job of describing the scope and potential of the nanotechnology marketplace and the position of technology leaders such as Biophan in enabling the nanotechnology revolution,” said Michael Weiner, Biophan CEO. “The article conveys the financial and investment potential that nanotechnology presents in healthcare and medical science, where Biophan holds key proprietary technologies.”
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin-film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 104 U.S. patents, licenses, or applications. This total includes 30 issued U.S. patents, 6 recently-allowed applications that will issue as patents in the near future, and 68 pending applications at various stages of examination at the U.S. Patent and Trademark Office. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE: BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Es ist wieder ein Trend in den Nanos erkennbar.Die Woche hat es ALTAIR schon gezeigt und andere Werte sind gut mitgezogen.
Nächste Woche erscheint die Buisness Week und da steht auf Seite 67 dann die Erwähnung mit BIOPHAN TECHNOLOGIE.
Es hat eine Menge zu bedeuten,dass BIPH gerade in dieser wichtigen!!! Zeitschrift Erwähnung findet.Mit einem dicken Ausrufezeichen sehe ich auch die Verbindung mit J&J,Siemens und BSX.Auffällig ist zur Zeit,dass in jeder Meldung eine Verbindung mit BSX geschaffen wird.
Erst nächste Woche wird die Zeitrischft erscheinen,mit genau diesem Artikel.Also dürften wir in der kommenden Woche mit einem weiteren Anstieg rechnen.Was es bedeutet,dass BIPH erwähnt wird,dürfte klar sein.
Der Nano-Trend lebt auf.Viele Werte gehen ab und finden Anerkenntnis.BIOPHAN TECHNOLOGIE ist einer der wichtigsten und vielversprechendste Firmen in der Zukunftssparte Nanotec.
Biophan CEO Discusses Company`s Technology Portfolio and Business Strategy in Interview with WallSt.Net, Available Online
BW5454 FEB 14,2005 3:01 PACIFIC 06:01 EASTERN
( BW)(NY-BIOPHAN)(BIPH) Biophan CEO Discusses Company´s TechnologyPortfolio and Business Strategy in Interview with WallSt.Net,Available Online
Business Editors/Health/Medical Writers
BIOWIRE2K
ROCHESTER, N.Y.--(BUSINESS WIRE)--Feb. 14, 2005--
Company Chief Reports on Progress in Licensing Proprietary Technology for New Generation of Biomedical Products
Biophan Technologies, Inc. (OTCBB: BIPH), a developer ofnext-generation biomedical technology, has announced the availabilityof an audio interview given by Company CEO, Michael Weiner, to onlineinvestor information service WallSt.net.
In the interview, Mr. Weiner described the scope of Biophan´sexpanding intellectual property portfolio in nanotechnology and otherareas that are enabling the development of new biomedical productsthat can solve critical issues in healthcare. He discussed theCompany´s product and technology development agreements with leadingmedical instrument makers such as Boston Scientific, and outlinedBiophan´s strategy to drive substantial revenue growth throughlicensing of its proprietary solutions to makers of products for thehealthcare and life sciences marketplace.
The ten-minute streaming audio interview can be accessed athttp://www.WallSt.net/. To listen, click on the BIPH ticker symbol onthe left hand column of the page or enter the BIPH symbol in the AudioSearch window. Registration to listen to the interview is free.
Among the specific market sectors areas Mr. Weiner discussed areBiophan´s leadership in development of proprietary solutions to allowimplanted medical devices, such as pacemakers, to be used safely inMagnetic Resonance Imaging (MRI) environments. The Company has alsosolved a range of problems that have traditionally prevented otherimplanted medical devices from being clearly and effectively imagedunder MRI.
In addition, Mr. Weiner elaborated on the value of Biophan´splanned acquisition of AMRIS, a leading German-based developer ofMRI-safe and image-compatible technology solutions and biomedicaldevices. The planned acquisition will significantly expand Biophan´sexisting international intellectual property portfolio, granting theCompany exclusive license to fifteen issued and pending patents,covering imaging of devices such as stents and other vascularimplants. Biophan currently holds a total of 104 U.S. patents,licenses, or applications.
About WallSt.net
WallSt.net, owned by Digital Wall Street, is an online opennetwork financial community that provides a number of services andtools to investors, including financial and market news, reports, andconferences. It can be found at http://www.WallSt.net.
ROCHESTER, N.Y., Feb 17, 2005 (BUSINESS WIRE) -- Biophan Technologies, Inc.
(OTCBB: BIPH), a developer of next-generation biomedical technology, announced
that it has been named to receive the Nano Science and Technology Institute's
(NSTI) Early Stage Company Award, to be presented at its February 23-25
conference in Tokyo, Japan.
The ICS-NSTI's Early Stage Company Award recognizes superior innovation and
achievement by development-stage companies providing leadership in the science
and business of nanotechnology. NSTI is a respected organization that works to
promote education, research and business development in nanoscience and related
fields. Biophan has developed a rich portfolio of patents and intellectual
property that provide a range of solutions to important problems in healthcare,
among them, the application of nanotechnology to improve the safety and
effectiveness of Magnetic Resonance Imaging (MRI), one of medicine's most
important diagnostic tools.
"We're gratified that Biophan's continuing advances in nanotechnology have been
recognized by the Nano Science and Technology Institute," said Michael Weiner,
Biophan's CEO. "The award is an important validation of Biophan's research and
development in applications of nanotechnology that have the potential to enable
substantial advances in healthcare and the life sciences, and to incorporate
nanotechnology into the multi-billion-dollar worldwide markets in medical
devices, drug delivery, power systems, and other sectors. Our company is built
on the development of intellectual property from the laboratory to the
marketplace, and the ISC-NSTI Early Stage Company Award helps demonstrate our
contributions to the nanoscience space."
The ICS-NSTI Early Stage Company Award includes a modest cash award and an
invitation for Biophan's representative to address attendees at the Tokyo
conference, to present the Company's advanced nanotechnology-based biomedical
solutions and research. Approximately 20,000 nanoscience research and business
professionals are expected to attend the conference.
In addition, Biophan has been accepted by NSTI into its Nanotech Ventures
program commencing at the Nanotech 2005 Conference and Trade Show on May 8-12,
in Anaheim, California. Biophan will make a presentation at that gathering, as
part of the organization's Nanotech 2005 Early Stage Company Review, a forum
designed to allow companies to showcase their technologies and solutions.
Bin mal auf 15.30 gespannt. Denke weiter UP!
Gruß
Biophan Issued Two New U.S. Patents Enabling Advances in MRI Compatibility and Safety for Medical Devices
ROCHESTER, N.Y.Biophan Technologies, Inc.Carolyn Hotchkiss, 585-214-2407orPress Interviews:Jennifer Gould, 212-843-8037
Additional Patents Strengthen Company's Intellectual Property Protection in Nanotechnology and Photonics
Biophan Technologies, Inc. (OTC BB: BIPH), a developer of next-generation biomedical technology, has announced the issuance of two new patents by the U.S. Patent and Trademark Office that further extend the Company's competitive edge in the marketplace for the rapidly emerging field of magnetic resonance imaging (MRI) safety and image compatibility for surgical instruments and implanted devices.
The new patents, involving nanomagnetic coatings and advanced fiber-optics, adds important capability to Biophan's overall offerings of proprietary solutions that make medical devices safe and image compatible within the MRI environment. They further substantiate Biophan's competitive edge and leadership position within the marketplace for improving more than $12 billion of medical devices that do not have MRI safety and image compatibility.
"These patent issuances continue Biophan's growth and business strategy to develop a base of protected intellectual property in key medical areas," said Michael Weiner, CEO of Biophan. "As we extend our patents and claims covering important medical innovations--such as the ability to make MRI-image-compatible and MRI-safe devices--we strengthen the certainty that manufacturers of medical equipment will license our technology and avoid the risk of infringement and litigation. The broad coverage that Biophan has been diligent in obtaining also makes it attractive to our customers to consider an exclusive license for certain fields of strategic interest to them, because they realize that our broad patent position will allow them to defend their exclusive position in market segments important to them."
One of the new patents covers new methods to produce a variety of nanomagnetic coatings to shield medical equipment within an MRI environment. It includes a broad claim regarding how these coatings can be used in a variety of applications, including the reduction of heating in medical devices under MRI; to selectively generate heat for cancer treatments or to control drug release; to reduce image artifacts under MRI; or to enable unimpeded MRI visualization of devices that have been traditionally difficult to see effectively under MRI.
The other newly issued patent extends the Company's protection for next-generation MRI-safe techniques utilizing fiber-optics to power biomedical sensors and therapeutic devices.
Fiber-optic cables are thin and flexible enough to fit into blood vessels and capillaries, and can carry extraordinarily large amounts of data. However, powering a remote biosensor at the end of the fiber optic cable has traditionally been a problem. The new Biophan patent teaches how a variety of sensors, probes, and medical therapies can be remotely powered and can communicate over a fiber-optic cable by powering the remote probe with short pulses of light. The light energy is converted to electrical energy to power the probes and to send data back to a device where they can be analyzed. This technology can be applied to devices used outside the body or part of an implantable device. The patent is one of more than twenty Biophan patents, issued or pending, that teach the use of photonics and fiber-optics in biosensing and disease treatment.
We are very pleased to be receiving broad patents for photonic applications that we believe can serve an important role in the future of medical devices, both interventional and implanted. We believe that a range of future implantable and surgical medical devices will use photonic solutions, and we are pleased to have a large and growing patent portfolio covering this emerging capability.
In related news, Biophan announced that it had closed a term sheet with a major biomedical device company, but due to confidentiality agreements governing the transaction, will not be announcing details until the transaction closes. "We are very pleased with the transaction and its forward progress," said Mr. Weiner. "The agreement will be more than adequate to provide the capital needed to enable our listing on a major stock exchange. We are in the process of preparing our listing application."
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin-film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 106 U.S. patents, licenses, or applications. This total includes 30 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 68 pending applications at various stages of examination at the U.S. Patent and Trademark Office. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Copyright © 2005 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.
News Copyright © 2005 Interest!ALERT All rights reserved.
<!-- This material may not be published, broadcast, rewritten or redistributed. -->
In in Verbindung stehenden Nachrichten verkündete Biophan, daß es eine Konditionenvereinbarung mit einer biomedizinischen Vorrichtung hauptsächlichfirma geschlossen hatte, aber wegen der Vertrauensabkommen wird die Regelung der Verhandlung, nicht Verkünden der Details, bis die Verhandlung schließt. " wir sind mit der Verhandlung sehr erfreut und sein Vorwärtsfortschritt," sagte Herrn Weiner. " die Vereinbarung ist mehr als ausreichend, das Kapital zur Verfügung zu stellen, das benötigt wird, um unserer Auflistung auf einer hauptsächlichbörse zu ermöglichen. Wir sind bei dem Vorbereiten unseres Antrages auf Börsenzulassung."
ich denke wir sind so ziemlich vor dem Deal
Biophan erhält zwei neue Patente zur Verbesserung der Kompatibilität und Sicherheit von medizinischen Vorrichtungen bei der Kernspintomographie
( BW)(NY-BIOPHAN)(BIPH) Biophan erhält zwei neue Patente zur Verbesserung der Kompatibilität und Sicherheit von medizinischen Vorrichtungen bei der Kernspintomographie
Redaktion Wirtschaft/Gesundheit/Medizin
BIOWIRE2K
ROCHESTER, N.Y.--(BUSINESS WIRE)-24. Feb. 2005-- Neue Patente verstärken die Absicherung des geistigen Eigentums des Unternehmens in der Nanotechnologie und Photonik
Biophan Technologies, Inc. (OTC BB: BIPH), ein Innovationsunternehmen, das biomedizinische Technologie der nächsten Generation entwickelt, meldet die Erteilung zwei neuer Patente durch das US-Patent- und Markenamt. Damit wird die Wettbewerbsposition des Unternehmens auf dem umkämpften Markt für Technologien zur Verstärkung der Sicherheit und Bildkompatibilität chirurgischer Instrumente und implantierter Vorrichtungen in der Kernspintomographie (MRI) weiter gestärkt.
Die neuen Patente betreffen nanomagnetische Beschichtungen und moderne Glasfaseroptik und sind eine wichtige Ergänzung des Gesamtangebots proprietärer Lösungen von Biophan, mit denen sich medizinische Vorrichtungen in Zukunft sicher und bildkompatibel innerhalb einer MRI-Umgebung anwenden lassen werden. Sie stärken außerdem die günstige Wettbewerbs- und Führungsposition von Biophan auf dem Markt für Technologien zur Verbesserung von medizinischen Vorrichtungen im Wert von umgerechnet 12 Milliarden USD, die derzeit für eine Verwendung in der Kernspintechnologie nicht sicher genug sind und Bildstörungen auslösen.
" Die Erteilung dieser Patente ist eine Fortsetzung der Wachstums- und Geschäftsstrategie von Biophan zur Entwicklung einer Basis an geschütztem, geistigem Eigentum in medizinischen Kernbereichen" , so Michael Weiner, CEO von Biophan. " Durch die Erweiterung unserer Patente und Ansprüche in Bezug auf wichtige medizinische Innovationen - beispielsweise die Möglichkeit, MRI-bildkompatible und -sichere Geräte herstellen zu können - stellen wir sicher, dass die Medizintechnikhersteller unsere Technologie lizenzieren und vermeiden die Risiken von Fälschungen und Rechtsstreitigkeiten. Der breit gefächerte Patentschutz, den wir anstreben, macht es auch für unsere Kunden attraktiv, eine Exklusivlizenz für bestimmte Gebiete, die für sie von strategischem Interesse sind, in Erwägung zu ziehen: sie erkennen nämlich, dass unser außerordentlich umfassender Patentschutz ihnen ermöglicht, ihre exklusive Position in den für sie wichtigen Marktsegmenten zu verteidigen."
Eines der neuen Patente betrifft neue Verfahren zur Herstellung verschiedener Nanomagnetbeschichtungen, um medizinische Geräte innerhalb einer MRI-Umgebung abzuschirmen. Die Ansprüche sind sehr weit gefasst und betreffen die Verwendung dieser Beschichtungen in unterschiedlichen Applikationen, beispielsweise zur Verringerung der Wärmeentwicklung in medizinischen Vorrichtungen während der Kernspintomographie, zur selektiven Erzeugung von Wärme zur Behandlung von Krebs oder zur Steuerung der Medikamentenfreisetzung, zur Verringerung von Bildartefakten in der Kernspintomographie oder für unbeeinträchtigte Visualisierung von Vorrichtungen in der Kernspintomographie, deren Darstellung bislang erschwert war.
Das andere, neu erteilte Patent erweitert den Schutz der Techniken des Unternehmens für mehr Sicherheit in der Kernspintomographie, indem Glasfaseroptik zum Antrieb von biomedizinischen Sensoren und Therapiegeräten eingesetzt wird.
Glasfaserkabel sind so dünn und flexibel, dass sie in Blutgefäße und Kapillaren eingeführt werden und außerordentlich große Datenmengen übertragen können. Allerdings stellte die Stromversorgung eines Biosensors am entfernten Ende des Glasfaserkabels bislang ein Problem dar. Das neue Patent von Biophan beschreibt Lösungen, mit denen verschiedene Sensoren, Sonden und medizinische Therapievorrichtungen durch Fernantrieb betrieben und zum Datenaustausch genutzt werden können, indem kurze Lichtimpulse an solche Sonden gesendet werden. Die Lichtenergie wird in elektrische Energie umgewandelt, mit der Sonden betrieben werden und mit der Daten zurück an ein Gerät gesendet werden, wo sie ausgewertet werden. Diese Technologie kann auf Geräte außerhalb des Körpers oder auf Teile einer implantierbaren Vorrichtung angewandt werden. Das Patent ist eines von über zwanzig Patenten Biophans, die entweder erteilt oder angemeldet sind und die Verwendung von Photonik und Glasfaseroptik bei Biosensoren und zur Behandlung von Krankheiten betreffen.
Das Unternehmen geht davon aus, dass seine weit gefassten Patente für Photonik-Anwendungen in Zukunft in der interventionellen und implantierten Medizintechnik eine wichtige Rolle spielen werden. Photonik wird in Zukunft voraussichtlich in sehr vielen implantierbaren und chirurgischen medizinischen Vorrichtungen zur Anwendung kommen und Biophan verfügt über ein großes und wachsendes Patentportfolio, das diese neuen Möglichkeiten abdeckt.
Biophan gab in einer weiteren Pressemeldung bekannt, dass es einen Vorvertrag (Term Sheet) mit einem großen Biomedizintechnikunternehmen abgeschlossen hat. Aus Gründen der Vertraulichkeit der Transaktionsbedingungen werden Einzelheiten jedoch erst nach Abschluss der Verhandlungen bekannt gegeben. " Wir sind mit dem Verlauf der Transaktion sehr zufrieden" , so Weiner. " Durch den Vertrag erhalten wir das Kapital für unseren geplanten Börsengang, dessen Antrag wir derzeit vorbereiten."
Über Biophan Technologies
Biophan Technologies entwickelt und vermarktet neueste Technologien, mit deren Hilfe sich biomedizinische Geräte sicher und problemlos mit Kernspintomographieausrüstungen betreiben lassen. Das Unternehmen entwickelt Einsatztechnologien für medizinische Implantatsysteme, wie beispielsweise Schrittmacher, und für interventionelle chirurgische Vorrichtungen, wie Katheter und Führungsdrähte, sowie für Stents und andere Implantate, die sich sicher und wirksam durch Kernspintechnologie darstellen lassen. Die Technologie wird außerdem zur Verbesserung von Kernspin-Kontrastmitteln verwendet und wurde auf andere Anwendungen erweitert, wie beispielsweise die Arzneistoff-Delivery und durch Körperwärme angetriebene Energiesysteme. Fortschritte in der Nanotechnologie und Thin-Film-Beschichtungen sind Bestandteil von vier Produktlinien von Biophan. Biophan konzentriert sich auf Wachstum durch Innovation und einen entwicklungsorientierten Führungsstil. Das Unternehmen und seine Lizenzgeber verfügen nun über insgesamt 106 US-Patente, Lizenzen oder Anmeldungen. Davon sind 30 erteilte US-Patente, 8 kürzlich angenommene Patente, die in Kürze erteilt werden, und 68 beantragte Patente, die sich in verschiedenen Prüfstadien beim US-Patent- und Markenamt befinden. Die Patente betreffen Gebiete wie die Nanotechnologie (Nanopartikelbeschichtungen), Hochfrequenzfilter, Polymercomposite, thermoelektrische Materialien für Batterien, die Strom aus Körperwärme erzeugen, und Photonik. Biophan hat Entwicklungspartnerschaften mit Boston Scientific (NYSE:BSX) und dem Ames Center for Nanotechnology der NASA abgeschlossen. Biophan arbeitet darauf hin, alle biomedizinischen Geräte sicher und problemlos mit der Kernspintechnologie zu kombinieren. Mehr Informationen über Biophan gibt es im Internet unter www.biophan.com. Die Informationsbroschüre für Anleger oder die aktuellen Videos der Reihe " Biophan 101" über Aspekte der von dem Unternehmen entwickelten biomedizinischen Lösungen der nächsten Generation stehen unter http://www.trilogy-capital.com/t
Vorsichtshinweis in Bezug auf zukunftsweisende Aussagen
Bei bestimmten, in dieser Pressemeldung enthaltenen Aussagen handelt es sich um zukunftsweisende Aussagen. Die tatsächlichen Ergebnisse können wesentlich von solchen hierin genannten oder stillschweigenden Aussagen abweichen und zwar als Ergebnis unterschiedlicher Faktoren, darunter, jedoch nicht ausschließlich: der Entwicklung der MRI-Technologien von Biophan; der Annahme der Patentanmeldungen von Biophan; der erfolgreichen Implementierung der Forschungs- und Entwicklungsprogramme von Biophan; der Akzeptanz der Produkte von Biophan auf dem Markt; von Wettbewerb und zeitlicher Abstimmung von Projekten und Trends bei der zukünftigen Geschäftsperformance, sowie anderen Faktoren, die in den Unterlagen aufgeführt sind, die Biophan regelmäßig bei der US-amerikanischen Börsenaufsichtsbehörde (der " SEC" ) einreicht. Diese Pressemeldung sollte demzufolge unter Beachtung dieser Unterlagen gelesen werden. Die hierin enthaltenen, zukunftsweisenden Aussagen gelten nur für das Datum dieser Pressemeldung und Biophan übernimmt keine Verpflichtung zur öffentlichen Aktualisierung solcher zukunftsweisenden Aussagen als aufgrund späterer Ereignisse oder Umstände.
Biophan: Neue Patente
24.02.2005 - 100 Prozent und mehr! Biotech-Aktien mit hohen Kurschancen. Weitere Infos: hier klicken.
Mit Kursgewinnen reagiert die Biophan-Aktien auf zwei neue Patente, die das Unternehmen durch das US-Patent- und Markenamt zugesprochen bekommen hat. „Die neuen Patente betreffen nanomagnetische Beschichtungen und moderne Glasfaseroptik und sind eine wichtige Ergänzung des Gesamtangebots proprietärer Lösungen“, heißt es in einer Pressmitteilung des Unternehmens vom Donnerstag.
( mic )
Transaction Enriches Biophan's Intellectual Property Portfolio,
Establishes Expanded European Market Presence
ROCHESTER, N.Y., Feb 25, 2005 (BUSINESS WIRE) --
Biophan Technologies, Inc. (OTCBB:BIPH), a developer of next-generation biomedical technology, today announced completion of the acquisition of a majority interest in AMRIS GmbH, bringing Biophan exclusive access to key patents in Magnetic Resonance Imaging (MRI) technology and a world renowned scientific staff. AMRIS, a leading innovator in MRI-safe and image-compatible medical devices and technology solutions, possesses a suite of technology patents that enable effective MRI imaging of a range of important medical devices, including stents and other vascular implants.
The newly-acquired AMRIS will be renamed Biophan-Europe, and will serve as Biophan's chief European marketing and research presence. AMRIS subsidiary, MRC Corporation, was included in the acquisition. The principals and personnel from AMRIS and its MRC subsidiary bring existing contractual and consulting agreements with many of the world's leading biomedical device and MRI machine manufacturers. As a result, the acquisition significantly expands Biophan's international technology and business relationships in the European medical device industry and the worldwide scientific community.
" This is a significant acquisition on many fronts for Biophan," said Michael Weiner, CEO of Biophan. " It brings us a strong combination of both world renowned scientific and medical personnel, and critical technology and patents that will enhance the adaptation of our MRI-related solutions. Additionally, the increased access to MRI testing capabilities will support our growing base of customers wishing to adapt their devices for MRI safety and MRI visualization, while providing new revenue sources to Biophan."
The acquisition enriches Biophan's intellectual property portfolio with exclusive licenses to fifteen issued and pending U.S. and International patents covering imaging of medical devices such as stents, vena cava filters, and other vascular implants.
One of the main benefits this transaction brings Biophan is the newly established relationship with Dr. Michael Friebe, and partner Dr. Andreas Melzer, M.D., Research Physician, Surgeon, and Chief Research Officer of AMRIS. Dr. Friebe is an internationally respected scientist and entrepreneur who has specialized in MRI-related physics and companies. Dr. Melzer is a professor of applied biomedical engineering, and a prolific innovator in the field, who has co-invented more than 30 patents and has authored over 150 publications.
" We are extremely excited that we have found a partner who is equally committed to the MRI technology and who provides complementary technologies, products, and markets," commented Dr. Friebe.
Dr. Friebe will lead Biophan-Europe, and will join Biophan's board of directors. Dr. Melzer will join the Biophan Scientific Advisory Board, and will lead many of Biophan's research and development projects.
Included in the transaction's technology portfolio are patents for covering a stent with a fine wire mesh, a proprietary process that can make stents of certain metals, such as Nitinol, visible under MRI. Today's stents have problems imaging within the stent structure, where potential restenosis (blockage), can occur. This transaction gives Biophan control of the three preferred solutions to stent visibility: 1) AMRIS' resonant circuit technology; 2) Biophan's thin-film nanomagnetic particle coating solution; and 3) Biophan's anti-antenna solution. Each of these three solutions is covered by issued U.S. patents and pending international patents. Biophan now controls multiple patents for solutions that make vena cava filters and other vascular implants imageable under MRI.
" Our solutions allow the non-invasive, MRI-based, imaging of these devices which today can only be accomplished through more complicated invasive procedures," said Mr. Weiner. " We believe these approaches will become an important part of the rapidly growing worldwide market for stents and vascular implants. Biophan's strategy, strengthened by the acquisition of AMRIS, is to offer our customers the broadest possible set of alternative solutions to making devices safe and visible. Our business is both to improve medical devices to benefit patients, and to provide our customers with competitive advantages," said Mr. Weiner.